Cowen analyst Phil Nadeau is out with a research note on shares of Dynavax (NASDAQ:DVAX) following updates presented at the American Society of Clinical Oncology (ASCO) …
Cowen’s Phil Nadeau sings the praises of this “undervalued” biotech stock, encouraged to see DVAX’s cancer drug SD-101 revealed well tolerated results in a mid-stage trial.
J.P.
Brian Abrahams believes there could be between 20% to 30% in upside potential waiting in the wings for DVAX shares.
Cantor’s Elemer Piros bets on 52% upside potential for DVAX stock following its 2017 performance.
Dynavax Technologies Corporation (NASDAQ:DVAX) announced that HEPLISAV-B™ (Hepatitis B Vaccine) for the prevention of hepatitis B in adults is now available for prescription in the …
Cowen believes Dynavax has an asset on its hands that fulfills a valuable unmet need.
Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S.
Dynavax Technologies Corporation (NASDAQ:DVAX) announced initiation of dosing in patients with non-small cell lung cancer (NSCLC). This multi-center, open label trial is designed …
Dynavax Technologies Corporation (NASDAQ:DVAX) announced that the U.S.